Ascletis Pharma Inc - Asset Resilience Ratio

Latest as of June 2025: 10.83%

Ascletis Pharma Inc (2VJ) has an Asset Resilience Ratio of 10.83% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Ascletis Pharma Inc (2VJ) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

€216.30 Million

≈ $252.88 Million USD Cash + Short-term Investments

Total Assets

€2.00 Billion

≈ $2.33 Billion USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Ascletis Pharma Inc's Asset Resilience Ratio has changed over time. See 2VJ net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Ascletis Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Ascletis Pharma Inc.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€216.30 Million	10.83%
Total Liquid Assets	€216.30 Million	10.83%

Asset Resilience Insights

Moderate Liquidity: Ascletis Pharma Inc has 10.83% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Ascletis Pharma Inc Industry Peers by Asset Resilience Ratio

Compare Ascletis Pharma Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Fortress Biotech Inc NASDAQ:FBIO	Biotechnology	11.59%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Apellis Pharmaceuticals Inc NASDAQ:APLS	Biotechnology	0.58%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
BioArctic AB (publ) ST:BIOA-B	Biotechnology	72.35%
Chengzhi Shareholding Co Ltd SHE:000990	Biotechnology	6.73%

Annual Asset Resilience Ratio for Ascletis Pharma Inc (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Ascletis Pharma Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	50.92%	€1.08 Billion ≈ $1.26 Billion	€2.12 Billion ≈ $2.48 Billion	-28.14pp
2023-12-31	79.06%	€1.97 Billion ≈ $2.30 Billion	€2.49 Billion ≈ $2.91 Billion	+78.63pp
2022-12-31	0.42%	€11.20 Million ≈ $13.09 Million	€2.66 Billion ≈ $3.11 Billion	+0.24pp
2021-12-31	0.18%	€5.20 Million ≈ $6.08 Million	€2.83 Billion ≈ $3.31 Billion	-14.33pp
2017-12-31	14.51%	€143.83 Million ≈ $168.15 Million	€991.25 Million ≈ $1.16 Billion	+13.46pp
2016-12-31	1.05%	€5.61 Million ≈ $6.56 Million	€536.26 Million ≈ $626.95 Million	--

pp = percentage points

About Ascletis Pharma Inc

F:2VJ Germany Biotechnology

Market Cap

$2.16 Billion

€1.85 Billion EUR

Market Cap Rank

#6152 Global

#923 in Germany

Share Price

€1.75

Change (1 day)

-2.23%

52-Week Range

€0.62 - €1.99

All Time High

€1.99